|Bid||10.13 x 1000|
|Ask||10.40 x 700|
|Day's Range||10.01 - 10.39|
|52 Week Range||3.73 - 13.41|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
ImmunoGen's (IMGN) shares shoot up more than 150% in a year's time on rapid pipeline progress, positive study data and strategic collaborations.
Biotech stocks continued to be in the red this week, with the losses worse than what the broader market suffered. Here's a list of key events associated with biotech stocks one needs to focus on, in the ...
Investors were generally pleased with a data drop over the weekend, but it wasn't enough to keep ImmunoGen from tanking for no apparent reason on Tuesday.
The volatile nature of biotech stocks is evident from the wild swings they experience in the wake of catalytic events, which in fact present profit-making opportunities for an astute investor. This week ...
ImmunoGen (IMGN) advances with lead ovarian cancer candidate, mirvetuximab soravtansine. Moreover, combo therapies with the candidate for the indication are underway.
ImmunoGen (IMGN) reports wider-than-expected loss in Q4. However, higher license and milestone fees drive substantial revenue rise year over year.
In this article I am going to calculate the intrinsic value of ImmunoGen Inc (NASDAQ:IMGN) using the discounted cash flows (DCF) model. If you want to learn more about thisRead More...
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 11 cents. Losses, adjusted for non-recurring costs, came to 10 cents per share. The results missed Wall Street expectations. ...
ImmunoGen (IMGN) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
ImmunoGen's (IMGN) significant progress with lead pipeline candidate, mirvetuximab soravtansine, might drive the stock in Q4.